Current Environment: Production

Medical Services

Specialties

Programs & Services

Languages

  • English

Education

Medical School

New York University School of Medicine

2001, New York, MA

Residency

University of Chicago

2004, Chicago, IL

Fellowship

University of Chicago

2008, Chicago, IL

Certifications

  • American Board of Pediatrics (Gastroenterology)

Professional History

Dr. Stacy Kahn completed her undergraduate degree in history at Washington University in St. Louis, and her post-baccalaureate premedical training at Bryn Mawr College in Pennsylvania. She attended New York University School of Medicine and then went on to complete her pediatric residency and pediatric gastroenterology fellowship at the University of Chicago. While at the University of Chicago, she also completed an ethics fellowship at the Maclean Center for Clinical Medical Ethics.

Clinically, Dr. Kahn’s interests have focused on the care of children with IBD, in particular she is interested in the care and management of teens and young adults with Crohn’s and colitis. While on the faculty at the University of Chicago, she founded and was the Director for the Transitional IBD Clinic. Dr. Kahn's other primary clinical focus is recurrent and refractory Clostridium difficile infection. She is a national expert and leader in the field of fecal microbiota transplantation (FMT) and performed the first colonoscopic FMT in a child.

Dr. Kahn's research interests include FMT for Clostridium difficile, FMT for inflammatory bowel disease, transition of care and self-management in IBD and research ethics. She is the director of the FMT research program at Boston Children’s Hospital and has led the development of the first national pediatric FMT registry.

Media

Managing Medical Issues

Looking for Answers: The Microbiome in Autism

Publications

  1. Higher alpha diversity and Lactobacillus blooms are associated with better engraftment after fecal microbiota transplant in inflammatory bowel disease. Sci Rep. 2024 08 06; 14(1):18188. View Abstract

  2. Fecal Microbiota Transplantation: Information for the Pediatrician. Pediatrics. 2023 Dec 01; 152(6). View Abstract

  3. Fecal Microbiota Transplant in Pediatric Solid Organ Transplant Recipients. Transplantation. 2023 09 01; 107(9):2073-2077. View Abstract

  4. Redefining Clostridioides difficile infection antibiotic response and clinical outcomes. Lancet Infect Dis. 2023 07; 23(7):e259-e265. View Abstract

  5. How to Write an Effective Letter of Medical Necessity. J Pediatr Gastroenterol Nutr. 2023 04 01; 76(4):407-409. View Abstract

  6. Higher alpha diversity and Lactobacillus blooms are associated with better engraftment after Fecal Microbiota Transplant in Inflammatory Bowel Disease. medRxiv. 2023 Feb 01. View Abstract

  7. Fecal Microbiota Transplantation for Clostridioides difficile Infection in Immunocompromised Pediatric Patients. J Pediatr Gastroenterol Nutr. 2023 04 01; 76(4):440-446. View Abstract

  8. Case 3-2023: A 16-Year-Old Girl with Abdominal Pain and Bloody Diarrhea. N Engl J Med. 2023 01 26; 388(4):358-368. View Abstract

  9. Fecal Microbiota Transplantation Across the Lifespan: Balancing Efficacy, Safety, and Innovation. Am J Gastroenterol. 2023 03 01; 118(3):435-439. View Abstract

  10. Breaking Down the Boxes-Time to Reshape Demographic Data. JAMA Pediatr. 2022 10 01; 176(10):1047. View Abstract

  11. Clostridioides difficile Infection in Hospitalized Pediatric Patients: Comparisons of Epidemiology, Testing, and Treatment from 2013 to 2019. J Pediatr. 2023 01; 252:111-116.e1. View Abstract

  12. Denials, Dilly-dallying, and Despair: Navigating the Insurance Labyrinth to Obtain Medically Necessary Medications for Pediatric Inflammatory Bowel Disease Patients. J Pediatr Gastroenterol Nutr. 2022 10 01; 75(4):418-422. View Abstract

  13. Efficacy and Outcomes of Faecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection in Children with Inflammatory Bowel Disease. J Crohns Colitis. 2022 06 24; 16(5):768-777. View Abstract

  14. Pediatric Fecal Microbiota Transplantation in Recurrent Clostridioides Difficile. Pediatr Ann. 2021 Dec; 50(12):e515-e521. View Abstract

  15. Fecal Microbiota Transplantation for Ulcerative Colitis: Dispelling the "Yuck Factor". J Pediatr Gastroenterol Nutr. 2021 12 01; 73(6):663-664. View Abstract

  16. Updates and Challenges in Fecal Microbiota Transplantation for Clostridioides difficile Infection in Children. J Pediatr Gastroenterol Nutr. 2021 10 01; 73(4):430-432. View Abstract

  17. Current Challenges in Fecal Microbiota Transplantation for Clostridioides difficile Infection in Children. Am J Gastroenterol. 2021 09 01; 116(9):1954-1956. View Abstract

  18. Fecal Calprotectin Is Highly Effective to Detect Endoscopic Ulcerations in Crohn's Disease Regardless of Disease Location. Inflamm Bowel Dis. 2021 06 15; 27(7):1008-1016. View Abstract

  19. Fecal Microbiota Transplantation for Recurrent C difficile Infection During the COVID-19 Pandemic: Experience and Recommendations. Mayo Clin Proc. 2021 06; 96(6):1418-1425. View Abstract

  20. Inflammatory Bowel Disease Presenting With Concurrent COVID-19 Multisystem Inflammatory Syndrome. Pediatrics. 2021 04; 147(4). View Abstract

  21. The Ethics of Feeding the Aspirating Child in an Age of Increasing Patient Complexity. J Pediatr Gastroenterol Nutr. 2020 11; 71(5):586-588. View Abstract

  22. Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry. Gastroenterology. 2021 01; 160(1):183-192.e3. View Abstract

  23. The Ethics of Feeding the Aspirating Child in an Age of Increasing Patient Complexity. J Pediatr Gastroenterol Nutr. 2020 Aug 20. View Abstract

  24. Letter: is unrealised adult height resulting from paediatric Crohn's disease associated with a potential reduction in lifetime earnings? Aliment Pharmacol Ther. 2020 08; 52(3):559-560. View Abstract

  25. Perceived effect of pediatric inflammatory bowel diseases on academics, college planning, and college adjustment. J Am Coll Health. 2022 04; 70(3):940-947. View Abstract

  26. Is it unethical to conduct placebo-controlled trials of faecal microbiota transplantation for recurrent Clostridioides difficile infection? Lancet Gastroenterol Hepatol. 2020 05; 5(5):432-433. View Abstract

  27. International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut. 2019 12; 68(12):2111-2121. View Abstract

  28. Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases. J Crohns Colitis. 2019 Aug 14; 13(8):1012-1024. View Abstract

  29. Response to: Treatment of (Recurrent) Clostridioides difficile Infections in Children and Adults. J Pediatr Gastroenterol Nutr. 2019 08; 69(2):e58-e59. View Abstract

  30. Risk-factors Associated With Poor Outcomes in VEO-IBD Secondary to XIAP Deficiency: A Case Report and Literature Review. J Pediatr Gastroenterol Nutr. 2019 07; 69(1):e13-e18. View Abstract

  31. Efficacy of Fecal Microbiota Transplantation for Clostridium difficile Infection in Children. Clin Gastroenterol Hepatol. 2020 03; 18(3):612-619.e1. View Abstract

  32. The Gut Microbiome: A Difficult Target for Translational Studies of Clostridium difficile Colonization. J Pediatr Gastroenterol Nutr. 2019 04; 68(4):463-464. View Abstract

  33. Risk-factors Associated with Poor Outcomes in VEO-IBD Secondary to XIAP Deficiency: A Case Report and Literature Review. J Pediatr Gastroenterol Nutr. 2019 Feb 07. View Abstract

  34. Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children: A Joint Position Paper From the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2019 01; 68(1):130-143. View Abstract

  35. Searching for superstool: maximizing the therapeutic potential of FMT. Nat Rev Gastroenterol Hepatol. 2018 07; 15(7):387-388. View Abstract

  36. Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis. Dig Dis Sci. 2018 May; 63(5):1294-1301. View Abstract

  37. Moving On: Transition Readiness in Adolescents and Young Adults With IBD. Inflamm Bowel Dis. 2018 02 15; 24(3):482-489. View Abstract

  38. Indirect Costs and Family Burden of Pediatric Crohn's Disease in the United States. Inflamm Bowel Dis. 2017 12; 23(12):2089-2096. View Abstract

  39. Reliability and validity of the Beliefs About Medication Scale in pediatric inflammatory bowel disease. J Child Health Care. 2017 Sep; 21(3):253-262. View Abstract

  40. Tracking microbial colonization in fecal microbiota transplantation experiments via genome-resolved metagenomics. Microbiome. 2017 05 04; 5(1):50. View Abstract

  41. What Teens Do Not Know Can Hurt Them: An Assessment of Disease Knowledge in Adolescents and Young Adults with IBD. Inflamm Bowel Dis. 2017 01; 23(1):89-96. View Abstract

  42. Transition of Care for Adolescents and Young Adults With Inflammatory Bowel Disease: The More We Learn, The Less We Know. J Pediatr Gastroenterol Nutr. 2016 11; 63(5):451-452. View Abstract

  43. Transition of Care for Adolescents and Young Adults with IBD: The More We Learn, the Less We Know. J Pediatr Gastroenterol Nutr. 2016 Jun 02. View Abstract

  44. The Transition From Pediatric to Adult Inflammatory Bowel Disease Care. Gastroenterol Hepatol (N Y). 2016 Jun; 12(6):403-6. View Abstract

  45. When Subjects Violate the Research Covenant: Lessons Learned from a Failed Clinical Trial of Fecal Microbiota Transplantation. Am J Gastroenterol. 2016 11; 111(11):1508-1510. View Abstract

  46. Feeling Fine: Anxiety and Depressive Symptoms in Youth with Established IBD. Inflamm Bowel Dis. 2016 Feb; 22(2):402-8. View Abstract

  47. Colonic Necrosis in a 4-Year-Old with Hyperlipidemic Acute Pancreatitis. Case Rep Pediatr. 2016; 2016:9123163. View Abstract

  48. Genetic and Metabolic Signals during Acute Enteric Bacterial Infection Alter the Microbiota and Drive Progression to Chronic Inflammatory Disease. Cell Host Microbe. 2016 Jan 13; 19(1):21-31. View Abstract

  49. Whole-exome Sequence Analysis Implicates Rare Il17REL Variants in Familial and Sporadic Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016 Jan; 22(1):20-7. View Abstract

  50. Can You Teach a Teen New Tricks? Problem Solving Skills Training Improves Oral Medication Adherence in Pediatric Patients with Inflammatory Bowel Disease Participating in a Randomized Trial. Inflamm Bowel Dis. 2015 Nov; 21(11):2649-57. View Abstract

  51. Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. Gastroenterology. 2015 Jul; 149(1):223-37. View Abstract

  52. Can we improve on the "see one, do one, teach one" paradigm in training fellows to care for patients with inflammatory bowel disease? Inflamm Bowel Dis. 2015 Apr; 21(4):766-7. View Abstract

  53. Transition of Care in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2014 Oct; 10(10):633-40. View Abstract

  54. Trajectories of oral medication adherence in youth with inflammatory bowel disease. Health Psychol. 2015 May; 34(5):514-21. View Abstract

  55. Fecal microbiota transplantation: an interest in IBD? Nestle Nutr Inst Workshop Ser. 2014; 79:101-14. View Abstract

  56. Patient perceptions of fecal microbiota transplantation for ulcerative colitis. Inflamm Bowel Dis. 2013 Jun; 19(7):1506-13. View Abstract

  57. Colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection in a child. Am J Gastroenterol. 2012 Dec; 107(12):1930-1. View Abstract

  58. An unusual case of an infant with failure to thrive. Pediatr Ann. 2012 Dec; 41(12):502-5. View Abstract

  59. What's in a name generator? Choosing the right name generators for social network surveys in healthcare quality and safety research. BMJ Qual Saf. 2012 Dec; 21(12):992-1000. View Abstract

  60. Studying the Enteric Microbiome in Inflammatory Bowel Diseases: Getting through the Growing Pains and Moving Forward. Front Microbiol. 2011; 2:144. View Abstract

  61. Fecal bacteriotherapy for ulcerative colitis: patients are ready, are we? Inflamm Bowel Dis. 2012 Apr; 18(4):676-84. View Abstract

  62. Massive intestinal bleeding in a child with superior mesenteric artery aneurysm and gastrointestinal tuberculosis. J Pediatr Gastroenterol Nutr. 2006 Aug; 43(2):256-9. View Abstract
BESbswy
BESbswy